Journal
BRITISH JOURNAL OF CANCER
Volume 101, Issue 3, Pages 504-510Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6605161
Keywords
BubR1; Aurora A; ovarian neoplasm; prognosis; recurrence-free survival
Categories
Funding
- Korean ministry of Education and Science [ROA-2008-000-20023-0]
- National University Hospital [0420080450]
- 21C Frontier Functional Genome Project [FG062-14]
- Korea Research Foundation [KRF-2005-C00097]
- Korean ministry of Health welfare and Family Affairs
- RCFC [R11-2005-009-04003-0]
- KOSEF
Ask authors/readers for more resources
BACKGROUND: Epithelial ovarian cancer is one of the most lethal malignancies, and has a high recurrence rate. Thus, prognostic markers for recurrence are crucial for the care of ovarian cancer. As ovarian cancers frequently exhibit chromosome instability, we aimed at assessing the prognostic significance of two key mitotic kinases, BubR1 and Aurora A. METHODS: We analysed paraffin-embedded tissue sections from 160 ovarian cancer patients whose clinical outcomes had been tracked after first-line treatment. RESULTS: The median recurrence-free survival in patients with a positive and negative expression of BubR1 was 27 and 83 months, respectively (P<0.001). A positive BubR1 expression was also associated with advanced stage, serous histology and high grade. In contrast, Aurora A immunostaining did not correlate with any of the clinical parameters analysed. CONCLUSION: BubR1, but not Aurora A, is a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers. British Journal of Cancer (2009) 101, 504-510. doi:10.1038/sj.bjc.6605161 www.bjcancer.com Published online 14 July 2009 (C) 2009 Cancer Research UK
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available